Bandol, France

Patrick Vlieghe



 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2014-2016

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Patrick Vlieghe

Introduction

Patrick Vlieghe is a notable inventor based in Bandol, France. He has made significant contributions to the field of peptide derivatives, particularly in their application as carriers for various molecules. With a total of 3 patents, his work has the potential to impact pharmaceutical and diagnostic industries.

Latest Patents

Vlieghe's latest patents focus on peptide derivatives and their use as vectors for molecules of interest. One of his inventions relates to peptide derivatives that serve as carriers for therapeutic molecules, imaging agents, or molecular probes. These innovations aim to facilitate the transport of these molecules across cell membranes, especially through the blood-brain barrier (BBB). Another patent emphasizes the preparation and application of peptide derivatives to enable the transport of pharmaceutical or diagnostic molecules across various physiological barriers, including the blood-spinal cord barrier (BSCB) and blood-retinal barrier (BRB).

Career Highlights

Throughout his career, Patrick Vlieghe has worked with prominent organizations such as Vect-Horus and the Centre National de la Recherche Scientifique. His experience in these institutions has allowed him to refine his expertise in peptide technology and its applications in medicine.

Collaborations

Vlieghe has collaborated with notable professionals in his field, including Michel Khrestchatisky and Marion David. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Patrick Vlieghe's innovative work in peptide derivatives showcases his commitment to advancing medical science. His patents hold promise for improving the delivery of therapeutic agents across critical physiological barriers.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…